Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis

Abstract

Background: Antimalarial drugs affect the central nervous system, but it is difficult to differentiate the effect of these drugs from that of the malaria illness. We conducted a systematic review to determine the association between anti-malarial drugs and mental and neurological impairment in humans. Methods: We systematically searched online databases, including Medline/PubMed, PsychoInfo, and Embase, for articles published up to 14th July 2016. Pooled prevalence, heterogeneity and factors associated with prevalence of mental and neurological manifestations were determined using meta-analytic techniques. Results: Of the 2,349 records identified in the initial search, 51 human studies met the eligibility criteria. The median pooled prevalence range of mental and neurological manifestations associated with antimalarial drugs ranged from 0.7% (dapsone) to 48.3% (minocycline) across all studies, while it ranged from 0.6% (pyrimethamine) to 42.7% (amodiaquine) during treatment of acute malaria, and 0.7% (primaquine/dapsone) to 55.0% (sulfadoxine) during prophylaxis. Pooled prevalence of mental and neurological manifestations across all studies was associated with an increased number of antimalarial drugs (prevalence ratio= 5.51 (95%CI, 1.05-29.04); P=0.045) in a meta-regression analysis. Headaches (15%) and dizziness (14%) were the most common mental and neurological manifestations across all studies. Of individual antimalarial drugs still on the market, mental and neurological manifestations were most common with the use of sulphadoxine (55%) for prophylaxis studies and amodiaquine (42.7%) for acute malaria studies. Mefloquine affected more domains of mental and neurological manifestations than any other antimalarial drug. Conclusions: Antimalarial drugs, particularly those used for prophylaxis, may be associated with mental and neurological manifestations, and the number of antimalarial drugs taken determines the association. Mental and neurological manifestations should be assessed following the use of antimalarial drugs.

Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions

“…Considering that HCQ and chloroquine have similar pharmacological properties, their toxicity profiles could be considered comparable. A meta-analysis [ 44 ] and a pharmacovigilance study on registry [ 45 ] confirmed the association between HCQ and psychiatric events. The mechanisms responsible for the psychiatric ADRs following HCQ exposure are not fully clarified.…”

The Ototoxicity of Antimalarial Drugs—A State of the Art Review

“…The most critical causes for discontinuation of MQ prophylaxis among travelers are ototoxic and neuropsychiatric adverse effects. The most typical adverse effects in malaria prophylaxis are headaches (15.5%) and dizziness (14.4%), with vertigo and visual difficulties reported in 1-10% of prophylactic users (69). In addition, a metaanalysis of 35 cohort studies (198,493 participants) comparing prophylactic MQ intake with placebo in adults, children and pregnant women indicated that MQ users were more likely to report nausea (high-certainty evidence) and dizziness (highcertainty evidence) (12).…”

Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines

“…Finally, in a meta-analysis of adverse event data from 51 studies involving quinoline and non-quinoline anti-malarials, primaquine at the labelled dose exhibited amongst the lowest risk of general neurologic and neuropsychiatric adverse events of all the anti-malarials evaluated [ 33 ].…”